Chinese authorities and biotech giants are pushing back against a new U.S. bill that could reshape global scientific collaboration—and sparking debates about innovation vs. security.
China Condemns 'Discriminatory' Move
Foreign Ministry spokesperson Mao Ning called the Biosecure Act—passed by the U.S. House this week—a politically charged attack on Chinese companies like WuXi AppTec and BGI Group. "The U.S. needs to abandon ideological bias and respect market principles," she urged during a Beijing press briefing.
What's in the Bill?
The legislation, approved 306-81, bars U.S. federal agencies from working with certain Chinese biotech firms over alleged national security risks. Supporters claim it protects Americans' DNA data and pharma supply chains, but critics argue the targeting process lacks transparency.
Companies Fight Back
WuXi AppTec denied involvement in human genome data collection, calling claims "false," while BGI Group warned the bill could "stifle global medical breakthroughs." Both saw stock dips, with WuXi dropping 10% in Hong Kong trading.
What’s Next?
The bill now heads to the Senate, where its fate remains uncertain. If passed, President Biden would need to sign it into law—potentially escalating U.S.-China tech tensions. Stay tuned for updates!
But…
